All In Biotech

Drug Trial Radar · NCT02797587

Studying Partial-agonists for Ethanol and Tobacco Elimination in Russians With HIV (St PETER HIV)

URBAN ARCH 4/5 Russia Cohort-Targeting HIV-comorbidities With Pharmacotherapy to Reduce Alcohol and Tobacco Use in HIV-infected Russians

Last checked: Nov 20, 2026Latest source record: Dec 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

400

Actual

Start

Jul 19, 2017

Primary completion

Apr 30, 2020

Study completion Dec 15, 2020

Sponsor

Lead sponsor
Boston Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
First posted
Jun 13, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized controlled trial (RCT) to compare the effects of varenicline, cytisine, and nicotine replacement therapy (NRT) to reduce: 1) alcohol use and craving, 2) smoking; and 3) inflammation and risk for coronary heart disease (CHD) and mortality among 400 HIV-infected Russians, with heavy alcohol consumption and tobacco use.

Conditions

  • HIV Infection
  • Alcohol Use
  • Smoking

Interventions

  • VareniclineDrug

    1 week starter kit followed by 1mg twice daily for 12 weeks.

  • CytisineDrug

    Multi-daily dosing, range 3-9 mg daily for 25 days.

  • Nicotine Replacement TherapyDrug

    Mouth spray dosing based on standard recommendations tapered over 8 weeks.

  • Varenicline PlaceboDrug

    1 week starter kit followed by 1 pill twice daily for 12 weeks.

  • Cytisine PlaceboDrug

    Multi-daily dosing for 25 days.

  • Nicotine Replacement Therapy PlaceboDrug

    Mouth spray dosing based on standard recommendations tapered over 8 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent heavy drinking days in past 30 daysTime frame: Participants will be followed for up to 12 months (primary endpoint at 3 month)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • First St. Petersburg Pavlov State Medical University

    Saint Petersburg, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.